Myriad Genetics Nears Spin-off Date for Pharma Business | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday that its board of directors has set the record and distribution dates for the spinoff of its wholly owned subsidiary, Myriad Pharmaceuticals.

The firm said that Myriad Genetics' shareholders of record on June 17 will receive on June 30 a pro-rata dividend of .25 share of Myriad Pharmaceuticals common stock for each share of Myriad Genetics held. Fractional shares will be paid in cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.